MabPlex International is a CDMO that provides services from biologics drug development to commercial manufacturing for the global biopharmaceutical and biotechnology industries. Founded in 2013 and led by Chairman and CEO Jianmin Fang, Ph.D., the company operates two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA). The company closed a $59.1m Series A financing. MabPlex intends to use the funds to upgrade its technology platform and to expand commercial production capacity domestically and abroad. Its operations span development through commercial manufacturing across its China and U.S. sites. The company targets global biopharma and biotech clients seeking development and contract manufacturing support.

Total raised

$59M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2019